Penumbra Q2 revenue $261.5M +25.5% YoY; raises FY2023 guidance to $1.05-1.07B

Penumbra Inc

2023-Q2 EPS reported $0.70 revenue$502,897,000

Revenue $261.5M (+25.5% YoY constant currency), U.S. 71%, international 29%.
Vascular segment $152.7M (+23.6%), neuro segment $108.8M (+28.3%).
GAAP operating income $17.9M vs loss $0.1M; non-GAAP operating income $20.3M vs $1.6M.
Gross margin 63.8% vs 64.3% YoY; R&D $21.5M, SG&A $127.4M.
FY2023 revenue guidance raised to $1.05-1.07B (24-26% growth); vascular to outpace, neuro below.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Penumbra Inc reported second quarter ended June 30, 2023 results: revenue $261.5 million.

Period: second quarter ended June 30, 2023
Revenue: $261.5 million
Result: reported results

Exact text from the filing

Revenue of $261.5 million in the second quarter of 2023, an increase of 25.5% as reported and in constant currency 1 compared to the second quarter of 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Penumbra Inc reported full year 2023 results: revenue $1.05 billion to $1.07 billion. Guidance raised.

Period: full year 2023
Revenue: $1.05 billion to $1.07 billion
Guidance: raised
Result: guidance update

Exact text from the filing

The Company is increasing its guidance for 2023 total revenue to be in the range of $1.05 billion to $1.07 billion

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Penumbra Inc filing history →

Source: SEC EDGAR

accession 0001321732-23-000086

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.